With a market cap of $21 billion, Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and ...

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on Friday ...

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...

Biogen believes that some of its new drugs, Eisai-partnered Leqembi for Alzheimer’s disease, Skyclarys for Friedreich’s ataxia and Zurzuvae for depression, have the potential to revive long ...

An appointment with Wendell Helveston, M.D., a neurologist in Hattiesburg, MS, led to a series of diagnostic tests, such as ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.